Kenneth A Carson

US Patent:

6548499, Apr 15, 2003

Filed:

Oct 20, 2000

Appl. No.:

09/622423

Inventors:

Kenneth G. Carson - Needham MA
David Thomas Connor - Ann Arbor MI
Jie Jack Li - Ann Arbor MI
Joseph Edwin Low - Brighton MI
Jay R. Luly - Wellesley MA
Steven Robert Miller - Ann Arbor MI
Bruce David Roth - Plymouth MI
Bharat Kalidas Trivedi - Farmington Hills MI

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 31495

US Classification:

514249, 544353, 544356

Abstract:

Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohns disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimers disease, graft versus host reaction, allograft rejections, or allergic diseases.

US Patent:

7186729, Mar 6, 2007

Filed:

Nov 13, 2002

Appl. No.:

10/487168

Inventors:

Jay R. Luly - Wellesley MA, US
Yoshisuke Nakasato - Shizuoka, JP
Etsuo Ohshima - Nagareyama, JP
Geraldine C. B. Harriman - Charlestown RI, US
Kenneth G. Carson - Needham MA, US
Shomir Ghosh - Brookline MA, US
Amy M. Elder - Arlington MA, US
Karen M. Mattia - Marlborough MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
Kyowa Hakko Kogyo Co., Ltd. - Tokyo

International Classification:

A01N 43/42
A61K 31/44
C07D 401/00
C07D 451/00
C07D 453/00

US Classification:

514291, 546 18, 546 20, 546 80, 546 81, 546 89, 546 93

Abstract:

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

US Patent:

7211672, May 1, 2007

Filed:

Oct 3, 2003

Appl. No.:

10/678872

Inventors:

Shomir Ghosh - Brookline MA, US
Amy M. Elder - Arlington MA, US
Kenneth G. Carson - Needham MA, US
Kevin Sprott - Boston MA, US
Sean Harrison - Belmont MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07D 215/38
C07D 215/44

US Classification:

546157, 546159, 514313, 514314

Abstract:

Disclosed herein are compounds represented by Structural Formula (I):Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2 (“CRTH2”) for the treatment of inflammatory disorders.

US Patent:

7271176, Sep 18, 2007

Filed:

Nov 13, 2002

Appl. No.:

10/487168

Inventors:

Jay R. Luly - Wellesley MA, US
Yoshisuke Nakasato - Shizuoka, JP
Etsuo Ohshima - Nagareyama, JP
Geraldine C. B. Harriman - Charlestown RI, US
Kenneth G. Carson - Needham MA, US
Shomir Ghosh - Brookline MA, US
Amy M. Elder - Arlington MA, US
Karen M. Mattia - Marlborough MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
Kyowa Hakko Kogyo Co., Ltd. - Tokyo

International Classification:

A01N 43/42
A61K 31/44
C07D 401/00
C07D 451/00
C07D 453/00

US Classification:

514291, 546 18, 546 20, 546 80, 546 81, 546 89, 546 93

Abstract:

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

US Patent:

7504508, Mar 17, 2009

Filed:

Apr 7, 2005

Appl. No.:

11/101208

Inventors:

Shomir Ghosh - Brookline MA, US
Amy M. Elder - Arlington MA, US
Kenneth G. Carson - Princeton NJ, US
Kevin T. Sprott - Boston MA, US
Sean J. Harrison - Belmont MA, US
Frederick A. Hicks - Somerville MA, US
Christelle C. Renou - Somerville MA, US
Dominic Reynolds - Cambridge MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07D 215/38

US Classification:

546112, 546152, 546159

Abstract:

Disclosed herein are compounds represented by Structural Formula (I) and (I-A):Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply “CRTH2” for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

US Patent:

7541365, Jun 2, 2009

Filed:

Nov 10, 2006

Appl. No.:

11/595653

Inventors:

Jay R. Luly - Wellesley MA, US
Yoshisuke Nakasato - Shizuoka, JP
Etsuo Ohshima - Nagareyama, JP
Geraldine C. B. Harriman - Charlestown RI, US
Kenneth G. Carson - Needham MA, US
Shomir Ghosh - Brookline MA, US
Amy M. Elder - Arlington MA, US
Karen M. Mattia - Marlborough MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
Kyowa Hakko Kogyo Co., Ltd. - Tokyo

International Classification:

A01N 43/42
A61K 31/44
C07D 455/04
C07D 491/00
C07D 221/00
C07D 221/06

US Classification:

514290, 514291, 546 79, 546 80, 546 89, 546 93, 546101

Abstract:

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by:.

US Patent:

7951950, May 31, 2011

Filed:

Feb 23, 2006

Appl. No.:

11/360885

Inventors:

Jeremy D. Little - Wakefield MA, US
Shomir Ghosh - Brookline MA, US
Sean Harrison - Belmont MA, US
Amy M. Elder - Arlington MA, US
Christelle C. Renou - Somerville MA, US
Kenneth G. Carson - Princeton NJ, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07D 215/38

US Classification:

546159

Abstract:

Disclosed are CRTH2 inhibitors represented by Structural Formula (I):.

US Patent:

8058287, Nov 15, 2011

Filed:

May 6, 2009

Appl. No.:

12/436271

Inventors:

Jay R. Luly - Wellesley MA, US
Yoshisuke Nakasato - Shizuoka, JP
Etsuo Ohshima - Nagareyama, JP
Geraldine C. B. Harriman - Charlestown RI, US
Kenneth G. Carson - Needham MA, US
Shomir Ghosh - Brookline MA, US
Amy M. Elder - Arlington MA, US
Karen M. Mattia - Marlborough MA, US

Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
Kyowa Hakko Kirin Co., Ltd. - Tokyo

International Classification:

C07D 491/00
C07D 498/00
C07D 515/00
A01N 43/42
A61K 31/44

US Classification:

514291, 546 89

Abstract:

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by:.